Summary by Futu AI
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 11,447 Class A shares of the company on 06/25/2024, as per the latest filing. The shares, valued at approximately $108,805.92, were originally acquired as founders shares on 09/01/2016 as part of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 77,289 shares were sold for gross proceeds of $684,271.04. The notice of the upcoming sale was filed on the same date as the planned sale, with the instruction for this transaction given on 08/18/2023.